One trial investigating the direct impact of SGLT2 inhibitors on arrhythmia burden in CRT patients is ongoing, but does not include BVP efficacy or cardiac remodelling as endpoints (94). This evidence concerns the gene SLC5A2 and cardiac arrhythmia.